Digi International Expands the Digi XBee 3 Family with Two New Global Cellular LTE Smart Modems
Digi International®, (NASDAQ: DGII), a leading provider of Internet of Things (IoT) connectivity solutions, today expanded its Digi XBee® 3 Global Cellular family of solutions with the unveiling of Digi XBee® 3 Cellular LTE Cat 1 and Digi XBee® 3 Cellular LTE-M/NB-IoT smart modems for global deployment. These new modules deliver the power and flexibility of the renowned Digi XBee ecosystem — pre-certified for global cellular deployments to accelerate development times and eliminate the costs associated with carrier certification processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005045/en/
Digi XBee® 3 Cellular LTE Cat 1 and Digi XBee® 3 Cellular LTE-M/NB-IoT smart modems for global deployment unveiled at Embedded World 2023. (Graphic: Business Wire)
The newest additions to the Digi XBee Global Cellular family are dependable, compact solutions with BLE and end-device carrier certifications that can be used worldwide and are equipped with Global Navigation Satellite System (GNSS) positioning. They deliver simplified and future-proof solutions for developers and original equipment manufacturers (OEMs) looking to add reliable cellular IoT connectivity to their devices or IoT gateways. With pre-integrated certifications, the XBee 3 Global family supports LTE Cat 1, LTE-M and NB-IoT networks, with 2G/3G fallback — for applications that require reliable cellular connectivity, anywhere in the world. These solutions support low-power applications such as meters, smart sensors and other fixed assets that send small portions of data.
Digi XBee Global Cellular family smart modems are designed to be provisioned, managed and monitored by Digi Remote Manager® (Digi RM). Additionally, they support MicroPython programming, Bluetooth, GNSS positioning for geolocation and Digi TrustFence® security.
“Our Digi XBee 3 Global Cellular family expands the XBee ecosystem of RF modules, gateways, adapters and software — giving OEMs access to the smallest, pre-certified modems for cellular networks that will save thousands in development time and money,” said Steve Ericson, Vice President and General Manager of Digi’s OEM Solutions division. “Pre-certification, along with the integration of advanced software and security, and a full ecosystem of tools supports rapid time-to-market.”
Digi XBee 3 Global Cellular Cat 1
Designed for applications that require higher throughput, the XBee 3 Cat 1 smart modem gives customers a single SKU for deployment of cellular products anywhere in the world. It includes 2G/3G fallback for use in regions and countries where Cat 1 isn’t available.
Digi XBee 3 Global Cellular LTE-M/NB-IoT
Offering low-power cellular connectivity, Digi XBee 3 LTE-M/NB-IoT modules are designed for applications that require data collection from edge devices — supporting higher data rates, lower latency and cell tower handoff, making it ideal for mobile applications and asset tracking.
Delivering the lowest power consumption and data transfer rates available, NB-IoT is ideal for battery-powered and passive devices, which transmit small amounts of data at intermittent times.
All smart modems within the XBee Cellular family solution include MicroPython programming resources to enable direct custom scripting, 2G/3G fallback to ensure connectivity, GNSS for accurate location services, OTA firmware updates and access to Digi Remote Manager for over-the-air software updates and monitoring. With built-in Digi TrustFence® security, identity and data privacy features, customers can tap into more than 175 controls to protect against new and evolving cyber threats. The Digi XBee Mobile App and Digi XBee Studio® tool suite simplify setup, configuration and testing. Digi XBee Data Plans are also available for a wide variety of cellular connectivity requirements.
Digi XBee 3 Global Cellular Family solutions are available now. For more information, visit: https://www.digi.com/products/embedded-systems/digi-xbee/cellular-modems.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005045/en/
Contact information
Peter Ramsay
Global Results Communications
digi@globalresultspr.com
949.307.5908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altris and Draslovka Partner to Scale Europe’s First Sodium-Ion Battery Technology Supply Chain15.1.2026 15:00:00 EET | Press release
Altris, a Swedish sodium-ion battery developer, and Draslovka, a global leader in specialty chemicals, have entered a strategic partnership to build Europe’s first industrial-scale sodium-ion cathode value chain. Under the comprehensive agreement that includes a total 19.3 MEUR in-kind investment by Draslovka in Altris, the two companies will scale fully connected production of Altris’ patented sodium-ion cathode active material (CAM) at Draslovka’s facility in Kolín, Czech Republic, supplying up to 350 tonnes of CAM annually. Draslovka and Altris are partnering to convert an existing line at Draslovka’s Kolín facility for production of Altris’ sodium-ion CAM, enabling rapid time-to-market and capital-efficient scale-up. Once ramped, the line will support production of up to 350 tonnes annually – a European-controlled supply equivalent to around 175 MWh of sodium-ion cell capacity. As part of the agreement, Draslovka is making a new in‑kind 19.3 MEUR strategic investment in Altris to c
Vantage Data Centers Completes £200M Tap of Existing £600M Industry-First EMEA Data Center Asset-Backed Securitization (ABS) and Adds New £54M Class B Tranche15.1.2026 15:00:00 EET | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised an additional £254 million in securitized term notes. £200 million was raised through a tap of the existing Class A-2 Notes while £54 million was raised from the new Class B Tranche. This builds on Vantage’s debut public issuance in 2024 raising £600 million, which was the first-ever EMEA data center ABS completed in sterling. The Class A-2 Notes are rated A-, A (low) and A by Standard & Poor’s, Morningstar DBRS and Scope Ratings, respectively. The Class B Notes are rated BBB- by Standard & Poor’s and BBB by Morningstar DBRS and Scope Ratings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115777091/en/ Vantage’s 148MW Cardiff, Wales, campus is one of Europe’s largest hyperscale data center campuses. The new notes will be used to refinance certain indebtedness in connection with CWL11 and CWL13 (including the
CPP Investments Increases Commitment to Canadian Market through Northleaf Capital Partners15.1.2026 15:00:00 EET | Press release
Canada Pension Plan Investment Board (CPP Investments) and Northleaf Capital Partners (Northleaf) today announced a significant expansion of their longstanding Canadian investment partnership, supporting the growth and scaling of domestic private companies. CPP Investments has committed to invest an additional C$750 million through its established Canadian mid-market program managed by Northleaf, bringing CPP Investments’ cumulative commitments to the manager to more than C$3 billion since inception. The customized mandate focuses on maximizing net returns through a diversified strategy that includes primary fund commitments to small and mid-market Canadian buyout funds, secondary investments, and direct co-investments focused on the domestic market. “There are compelling investment opportunities in the Canadian market, and our two-decade long partnership with Northleaf has proven to be an effective and scalable way to invest in homegrown businesses with patient, long-term capital,” sa
QPS Selects Oracle Argus Safety Database to Enhance Pharmacovigilance in Clinical Trials15.1.2026 14:57:00 EET | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/ Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC. The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements. “Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Dere
InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease15.1.2026 14:30:00 EET | Press release
InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™ discovery platform – designed to optimize candidates toward superior signaling profiles – with Alveus’s deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic disease. While financial terms remain undisclosed, the agreement includes an upfront payment and eligibility for future development, regulatory, and commercial milestones. “We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx. “O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom